Congratulations to #OurImperial Professor Sir Peter John Barnes (of @ImperialNHLI) who has been recognised with the title of Knights Bachelor in the #KingsBirthdayHonours for services to Respiratory Science. The full #BDHonours23 list: https://t.co/Szvkr0uAa9

Get in touch with Mareike (she’ll be at the #ERS2022 so a great chance to meet F2F)! She’s a driving force of driving in cellular senescence in chronic lung disease, doing cutting edge techniques and will actually be in the lab teaching you everything you need to know.

JCI Insight - IL-36 receptor agonist and antagonist imbalance drives neutrophilic inflammation in COPD https://t.co/GeelIipycA - At last this paper is out due to all the hard work of @jrbaker88 @COPDUK @ImperialNHLI

Great presentation by @Mkg_Lehmann on cellular senescence in the epithelium and the role it may play on lung regeneration. #ATS2022

Big thanks to @m_konigshoff and @Mkg_Lehmann for organising a fantastic postgraduate course on cellular senescence and lung disease at #ATS2022. Great line up of speakers and learnt soo much.

Happening now #senescence pg course @ #ats2022 @ATS_RCMB. @m_konigshoff kicking off the session on aging which surprisingly is a rather young research field. @jrbaker88 @corrine_kliment chairing the course. I am so excited to be here IN PERSON!

@jrbaker88 @ATS_RCMB in our postgraduate course on #cellularsebescence talking about inflammaging in the #lung. Low grade chronic inflammation is found in aging. But response to damage is reduced. What is the role in the lung? #thefutureisbright

Looking forward to learning from the other speakers - an amazing lung senescence all-star team put together by @m_konigshoff and @corrine_kliment for #ATS2022 @ATS_RCMB

Huge thanks to all the team involved in both this work and the original Stoic trial! Thanks to @MonaBafadhel and team for welcoming up to Oxford last year. @SanjayResp @LouiseDResp @russell_doc @jodiegiffo

Also thanks to @p_openshaw and @FelicityLiew for their commentary piece on the manuscript. With their great figure on early mucosal events and disease outcomes in Covid-19 7/7

Finally, network analysis of inflammatory mediators in the nasal mucosa showed inhaled budesonide increased the anti-inflammatory (IL-10) and reduced T2 inflammatory response. Budesonide treatment appeared to normalise the anti-viral and T2 hyperinflammatory response. 6/7

As well as looking at the nasal mucosa, we examined patient sera, showing that altered inflammatory and virally induced mediators remained changed in the sera nearly a month after infection (most of these patients had only mild disease) 5/7

In the Stoic trial, 11 patients sought medical attention, with these patients showing a blunted antiviral response. Suggesting an appropriate antiviral inflammatory response is required in early disease. 4/7

We then showed that in those treated with #budesonide, for up to 7 days, they had reduced levels of IL-33 (decreased epithelial damage?) and elevated CCL17 (better T-cell response?) and also that their IL-10 response was improved 3/7

We first examined what happens at the nasal mucosa during the early stages of the disease (1-7 days post symptoms starting), showing increased interferon response, Th2 inflammation and viral induced chemokines. 2/7

Great to finally have this out in @LancetRespirMed! Here, we tried to understand the mechanism(s) by which the inhaled corticosteroid #budesonide reduced patients who clinically declined during #COVID19 in the Stoic clinical trial. A thread 🧵1/7

Thank you @LancetRespirMed for highlighting the STOIC team’s latest work. We show that using budesonide early in COVID-19 switches the nasal immune response to a beneficial one. We can probably also identify those who are going to deteriorate from nasal immune profile.

Do not miss our Postgraduate courses on #Cellularsenescence and #Drugdevelopment featuring leaders in the field. Sign up by tmrw https://t.co/E0rZsZnuQV https://t.co/JnlkvagDRi @m_konigshoff @jrbaker88 @corrine_kliment @mivukmiro @KaminskiMed @CShaver_MD

#ATS2022. Register today for our Postgraduate course on #CellularSenescence featuring talks on basic senescence biology, tools to study senescence and ways to translate this in the clinics to #cureIPF #CureCOPD. Check out this fantastic lineup of speakers. https://t.co/E0rZsZnuQV

Our work showing that early use of inhaled budesonide changed the airway immunology pattern in COVID-19. Proud of our team @jrbaker88 @LouiseDResp @COPDUK @jodiegiffo @SanjayResp @russell_doc Steven, Mahdi and Dan